The current valuation of nearly $200 million has to be including a fair bit for Axiron already. And the Phase III Axiron trial was relatively low risk, so I don't expect the annoucement of results from that to change market sentiment much.
A partnering deal for Axiron, on the other hand, could be a big event, especially if it includes a large up front payment. That should be enough to alleviate any funding issues (and make any capital raisings unnecessary), but it could conceivably be much more - US$100 million or more isn't inconceivable.
A good EU partnership for Ellavie could also be significant. It's a smaller market than the US market, but transdermals make up a larger share of it. And Acrux will be offering a partner a registered drug, not the Phase II success it had when it originally partnered Evamist with Vivus.
- Forums
- ASX - By Stock
- ACR
- price action
price action, page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.69M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 434 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 17258 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 434 | 0.054 |
2 | 16865 | 0.053 |
2 | 293669 | 0.052 |
3 | 119539 | 0.051 |
2 | 217490 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 17258 | 1 |
0.059 | 18000 | 1 |
0.060 | 670 | 1 |
0.061 | 100000 | 1 |
0.062 | 116100 | 2 |
Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
Day chart unavailable